St. John's wort
This article was originally published in The Tan Sheet
Executive Summary
Flawed endpoints, study design, analysis by Vanderbilt researchers in St. John's wort/depression trial charged by researchers, consultants, CRN reps in letters to the editor appearing in July 4 Journal of the American Medical Association. Trial by Richard Shelton, MD, et al., Vanderbilt University Medical Center, which found botanical to have no advantage over placebo for major depression, was published in April 18 JAMA (1"The Tan Sheet" April 23, p. 10). Shelton et al. defend their study protocol, saying "the simple placebo-controlled trial is a widely accepted design," and note their article conceded possible efficacy of herbal in treating mild-to-moderate depression
You may also be interested in...
St. John's Wort Prior Study Limitations Stressed In JAMA Research
Previous studies of St. John's wort have had numerous flaws - such as small sample sizes and low doses - a recent study led by Richard Shelton, MD, Vanderbilt University, et al., states.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands